摘要
Notch信号通路是一个进化上保守的发育网络,对胚胎发育和出生后组织生长调控的、维持体内平衡和自我修复十分关键。当Notch跨膜的配体与附近细胞上的跨膜型受体结合时,信号就开始产生了。连续水解生成一个激活的易位到细胞核上的Notch片段,在那里它驱动典型Notch靶基因的活化。在骨骼肌中,Notch信号控制肌细胞和干细胞生命。在人体软组织中,肉瘤横纹肌肉瘤因产生骨骼肌标志物而被认为与骨骼肌有关,Notch信号也发现上调和失调。本文介绍了正常胚胎和出生后发育过程的中Notch信号、最近发现的在肌营养不良时发生的异常Notch信号、在横纹肌肉瘤和相关的软组织肉瘤胚胎变异时Notch信号通路的上调和机制、与其它信号途径如Hippo、Hedgehog、Wnt和TGF-β的相互作用。本文总结了抑制Notch信号通路在治疗如人横纹肌肉瘤等肿瘤中的作用的最新进展。
关键词: Notch、胚胎性横纹肌肉瘤、肌肉骨骼、肌肉、肌营养不良、靶向治疗、儿童癌症。
图形摘要
Current Drug Targets
Title:Recent Insights into Notch Signaling in Embryonal Rhabdomyosarcoma
Volume: 17 Issue: 11
Author(s): Beatrice Conti, Katherine K. Slemmons, Rossella Rota, Corinne M. Linardic
Affiliation:
关键词: Notch、胚胎性横纹肌肉瘤、肌肉骨骼、肌肉、肌营养不良、靶向治疗、儿童癌症。
摘要: The Notch signaling pathway is an evolutionarily conserved developmental network critical for embryonic and postnatal regulation of tissue growth, homeostasis, and repair. Signaling is initiated when transmembrane Notch ligands bind to transmembrane Notch receptors on nearby cells. Sequential proteolytic steps generate an activated Notch fragment that translocates to the nucleus, where it drives activation of canonical Notch target genes. In skeletal muscle, Notch signaling governs myogenic cell fate and stem cell maintenance. In the human soft tissue sarcoma rhabdomyosarcoma, which bears markers of skeletal muscle commitment and so is thought to be related to the skeletal muscle lineage, Notch signaling is also found to be upregulated and dysregulated. This review provides an overview of Notch signaling during normal embryonic and postnatal myogenesis, information on the recently discovered aberrant Notch signaling occurring in muscular dystrophies, the upregulation and mechanism of Notch signaling in the embryonal variant of rhabdomyosarcoma and related soft tissue sarcomas, and Notch cross-talk with other metazoan developmental pathways including Hippo, Hedgehog, Wnt, and TGF-β. The review concludes with updates on current promising efforts to target and inhibit Notch signaling in human sarcomas including rhabdomyosarcoma.
Export Options
About this article
Cite this article as:
Beatrice Conti, Katherine K. Slemmons, Rossella Rota, Corinne M. Linardic , Recent Insights into Notch Signaling in Embryonal Rhabdomyosarcoma, Current Drug Targets 2016; 17 (11) . https://dx.doi.org/10.2174/1389450116666150907105756
DOI https://dx.doi.org/10.2174/1389450116666150907105756 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hotspot Mutations in DICER1 Causing GLOW Syndrome-Associated Macrocephaly <i>via</i> Modulation of Specific microRNA Populations Result in the Activation of PI3K/ATK/mTOR Signaling
MicroRNA HIV-1 Tat Disrupts CX3CL1-CX3CR1 Axis in Microglia via the NF-κBYY1 Pathway
Current HIV Research PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets Recent Therapeutic Advances for Treating Medulloblastoma: Focus on New Molecular Targets
CNS & Neurological Disorders - Drug Targets Imaging Reporters and Multimodal Molecular Bio-Imaging: A Database of Available Probes for Multi-Modality Bio-Imaging of Reporter Gene Expression
Recent Patents on Medical Imaging From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry Network-Based Strategies Can Help Mono- and Poly-pharmacology Drug Discovery: A Systems Biology View
Current Pharmaceutical Design Translational Research of Photodynamic Therapy with Acridine Orange which Targets Cancer Acidity
Current Pharmaceutical Design The Role of YY1 in Oncogenesis and Its Potential as a Drug Target in Cancer Therapies
Current Cancer Drug Targets p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design Antiproliferative and Proapoptotic Effects of the TrK-inhibitor GW441756 in Human Myosarcomas and Prostatic Carcinoma
Current Signal Transduction Therapy Repressing the Activity of Protein Kinase CK2 Releases Mitochondria-Mediated Apoptosis in Cancer Cells
Current Drug Targets Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Current Medicinal Chemistry Genetic Predisposition to Neonatal Tumors
Current Pediatric Reviews Docking and QSAR Studies of Aryl-valproic Acid Derivatives to Identify Antiproliferative Agents Targeting the HDAC8
Anti-Cancer Agents in Medicinal Chemistry Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine
Current Pharmaceutical Design Interaction of ABC Multidrug Transporters with Anticancer Protein Kinase Inhibitors: Substrates and/or Inhibitors?
Current Cancer Drug Targets microRNA-133: Expression, Function and Therapeutic Potential in Muscle Diseases and Cancer
Current Drug Targets NBN Polymorphysms and Cancer Susceptibility: A Systematic Review
Current Genomics Imatinib Reduces the Vasculogenic Potential of Plastic Tumor Cells
Current Angiogenesis (Discontinued)